PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Methotrexate

Drugs in development · updated 30 October 2026

Methotrexate: clinical trials and development status

Other names and codes: Jylamvo, Reditrex, Xatmep, Rasuvo

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 18 August 2016

As of 30 October 2026 Methotrexate is in 175 active clinical trials (recruiting or ongoing, phases I–III) for 115 diseases. The most advanced phase is III.

175Active trials
IIIMost advanced phase
115Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Methotrexate and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 115 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Precursor lymphoblastic lymphoma/leukemiaIII38NCT03007147
Burkitt lymphomaIII22NCT02101853
Acute biphenotypic leukaemiaIII14NCT03007147
Acute myeloid leukemiaIII11NCT04293562
Myelodysplastic SyndromesIII9NCT05457556
Rheumatoid arthritisIII9NCT03414502
LeukemiaII–III8NCT03117751
Precursor T-cell lymphoblastic leukemiaIII8NCT02112916
LymphomaII–III7NCT07072585
Precursor B-cell lymphoblastic leukemiaIII7NCT03914625
Graft-versus-host diseaseIII6NCT06615050
OsteosarcomaIII4NCT00470223
Down syndromeIII3NCT03914625
Head and neck squamous cell carcinomaIII3NCT05751512
Hematologic neoplasmIII3NCT07689630
MetastasisII–III3NCT06719479
Arthritis, JuvenileIII2NCT03728478
Ectopic pregnancyII–III2NCT07842796
Extranodal NK/T-cell lymphoma, nasal typeIII2NCT07678229
Systemic lupus erythematosusIII2NCT06965244
Bronchiolitis obliterans syndromeIII1NCT06615050
Cutaneous lupus erythematosusIII1NCT06965244
Diffuse sclerodermaIII1NCT06936215
Epstein–Barr virus infectionIII1NCT07678229
Langerhans-cell histiocytosisII–III1NCT02205762
SarcoidosisIII1NCT03593759
SarcomaIII1NCT00470223
Accelerated phase chronic myelogenous leukemiaII5NCT01424982
Blast CrisisII5NCT01424982
Myeloproliferative disordersII5NCT06265584

Everything on Methotrexate

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch